1. Home
  2. ROIV vs KNX Comparison

ROIV vs KNX Comparison

Compare ROIV & KNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Roivant Sciences Ltd.

ROIV

Roivant Sciences Ltd.

HOLD

Current Price

$21.67

Market Cap

14.1B

Sector

Health Care

ML Signal

HOLD

Logo Knight-Swift Transportation Holdings Inc.

KNX

Knight-Swift Transportation Holdings Inc.

HOLD

Current Price

$53.19

Market Cap

7.0B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
ROIV
KNX
Founded
2014
1989
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trucking Freight/Courier Services
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
14.1B
7.0B
IPO Year
N/A
1994

Fundamental Metrics

Financial Performance
Metric
ROIV
KNX
Price
$21.67
$53.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
17
Target Price
$21.94
$54.18
AVG Volume (30 Days)
6.7M
3.2M
Earning Date
11-10-2025
01-21-2026
Dividend Yield
N/A
1.35%
EPS Growth
N/A
280.63
EPS
N/A
0.88
Revenue
$20,329,000.00
$7,477,640,000.00
Revenue This Year
N/A
$2.37
Revenue Next Year
$376.94
$5.55
P/E Ratio
N/A
$60.64
Revenue Growth
N/A
N/A
52 Week Low
$8.73
$36.69
52 Week High
$22.45
$61.51

Technical Indicators

Market Signals
Indicator
ROIV
KNX
Relative Strength Index (RSI) 62.44 73.13
Support Level $20.14 $49.50
Resistance Level $21.48 $53.50
Average True Range (ATR) 0.71 1.54
MACD 0.00 0.57
Stochastic Oscillator 65.96 92.37

Price Performance

Historical Comparison
ROIV
KNX

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

About KNX Knight-Swift Transportation Holdings Inc.

Knight-Swift is the largest full-truckload carrier in the US, with a diversified transportation offering. Pro forma for the US Xpress deal, about 82% of revenue derives from Knight's asset-based trucking business, with full truckload (for-hire dry van, refrigerated, and dedicated contract) making up 69% and less than truckload 13%. Truck brokerage and other asset-light logistics services make up 9% of revenue, with intermodal near 6%. Knight's intermodal operations use the Class I railroads for the underlying movement of its shipping containers and include drayage (regional trucking services to and from inland intermodal ramps/terminals). The remainder of revenue reflects services offered to shippers and third-party truckers, including equipment maintenance and leasing.

Share on Social Networks: